Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | PTPRF | P10586 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7633092 | 1.00 | IDO1 (0.38) | IDO1GAAL3MBTL1SLC18A3HPGD | |
| Bromide SCHEMBL3322091 | 1.00 | IDO1 (0.38) | IDO1GAAL3MBTL1SLC18A3HPGD | |
| Bromide SCHEMBL10533526 | 0.98 | IDO1 (0.37) | IDO1GAAL3MBTL1SLC18A3HPGD | |
| Bromide SCHEMBL2447458 | 0.98 | GAA (0.36) | IDO1GAAL3MBTL1SLC18A3HPGD | |
| SCHEMBL29515524 | 0.98 | IDO1 (0.39) | IDO1GAAL3MBTL1SLC18A3HPGD | |
| Hydrochloric Acid SCHEMBL7629171 | 0.95 | IDO1 (0.38) | IDO1GAAL3MBTL1SLC18A3HPGD | |
| Iodide SCHEMBL7629435 | 0.95 | IDO1 (0.38) | IDO1GAAL3MBTL1SLC18A3HPGD | |
| Iodide SCHEMBL7628894 | 0.95 | IDO1 (0.38) | IDO1GAAL3MBTL1SLC18A3HPGD | |
| Hydrochloric Acid SCHEMBL4387947 | 0.95 | IDO1 (0.38) | IDO1GAAL3MBTL1SLC18A3HPGD | |
| Iodide SCHEMBL7633294 | 0.95 | IDO1 (0.38) | IDO1GAAL3MBTL1SLC18A3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6316575-B1 | MELT TRANSESTERIFICATION OF DIOL COMPOUND AND CARBOANTE COMPOUND USING CATALYST COMPRISING A PHOSPHORUS-CONTAINING BASIC COMPOUND QUATERNARY PHOSPHONIUM SALT TO FORM POLYCARBONATE | IDEMITSU KOSAN CO., LTD. (JP) | 2001-11-13 | — | — | US | claimed |
| EP-0329021-B1 | Preparation of advanced epoxy resins and dihydric phenols in the presence of phosphonium compounds | DOW CHEMICAL CO (US) | 1994-01-26 | — | — | EP | claimed |
| EP-0329021-A2 | Preparation of advanced epoxy resins and dihydric phenols in the presence of phosphonium compounds | THE DOW CHEMICAL COMPANY (US) | 1989-08-23 | — | — | EP | claimed |
| US-4808692-A | Preparation of advanced epoxy resins from epoxy resins and dihydric phenols in the presence of phosphonium compounds | THE DOW CHEMICAL COMPANY (US) | 1989-02-28 | — | — | US | claimed |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3700956-B1 | CATALYSTS FOR MAKING OXAZOLIDINONE MATERIALS | HUNTSMAN INT LLC (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119308018-A | Chiral zinc-based metal halide monocrystal material and preparation method and application thereof | 江西铜业技术研究院有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-118373846-A | Cerium (III) -based metal halide transparent glass scintillator and preparation method and application thereof | 中国计量大学 | 2024-07-23 | — | — | CN | disclosed |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-23 | — | — | US | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-4225761-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| US-5122523-A | Hypotensive agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| WO-1991016888-A1 | SPIRO[BENZOFURANCYCLOALKANE]CARBOXAMIDES AS 5HT3 ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| EP-0414160-A2 | Process for preparing advanced epoxy resins | THE DOW CHEMICAL COMPANY (US) | 1991-02-27 | — | — | EP | disclosed |
| WO-1991001975-A1 | CYCLOALKYLENAZOLES, PROCESS FOR PREPARING THEM, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE TO MANUFACTURE DRUGS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-02-21 | — | — | WO | disclosed |
| EP-0411735-A1 | Cycloalkylenazoles, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicines | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-02-06 | — | — | EP | disclosed |
| EP-0329021-A2 | Preparation of advanced epoxy resins and dihydric phenols in the presence of phosphonium compounds | THE DOW CHEMICAL COMPANY (US) | 1989-08-23 | — | — | EP | disclosed |
| EP-0309766-A2 | N-acylamino acid derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
| US-4808692-A | Preparation of advanced epoxy resins from epoxy resins and dihydric phenols in the presence of phosphonium compounds | THE DOW CHEMICAL COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | IDO1 4752/4885GAA 1085/4885L3MBTL1 4286/4885 |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | IDO1 4795/4885GAA 956/4885L3MBTL1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.